Mabwell (Shanghai) Bioscience Co Ltd is a China-based company principally engaged in the research and development of new molecular entity drugs. The Company’s business includes the research, development, transfer, technical services for and production and sales of new pharmaceutical and chemical technologies and new pharmaceutical products. The Company owns one Core Product 9MW2821 (bulumtatug fuvedotin) (“BFv”), a Nectin cell adhesion molecule 4 (“Nectin-4”) targeting antibody-drug conjugate (“ADC”) (the “Nectin-4 targeting ADC”). The Company sells pharmaceutical products to third-party contract sales organizations. Its out-licensing arrangements business includes Licenses of intellectual property rights, research and development services, milestone payments and royalties.

© Copyright 1996-2026 irasia.com Ltd. All rights reserved.

DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website. TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website.